ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Total Liabilities
ScinoPharm Taiwan Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Total Liabilities
NT$1.4B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Total Liabilities
NT$5.8B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
8%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Total Liabilities
NT$6.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
9%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Total Liabilities
NT$1.7B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Total Liabilities
NT$18.9B
|
CAGR 3-Years
23%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Total Liabilities
NT$5.3B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Total Liabilities?
Total Liabilities
1.4B
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Total Liabilities amounts to 1.4B TWD.
What is ScinoPharm Taiwan Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-3%
Over the last year, the Total Liabilities growth was 4%. The average annual Total Liabilities growth rates for ScinoPharm Taiwan Ltd have been 6% over the past three years , and -3% over the past ten years .
You don't have any saved screeners yet